Search Results
Aug 10, 2026, 07:00 ET Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
As previously announced on July 14, 2026, Avere and NextCure, Inc. (Nasdaq: NXTC) ("NextCure") have entered into a definitive merger agreement for an all-stock transaction. Upon completion of the transaction, which is expected to
More news about: Avere Therapeutics
Jul 24, 2026, 16:38 ET Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders
multimedia:https://www.prnewswire.com/news-releases/halper-sadeh-llc-is-investigating-whether-veee-nxtc-tcbk-fhb-are-obtaining-fair-deals-for-their-shareholders-302834368.htmlSOURCE
More news about: Halper Sadeh LLP
Jul 22, 2026, 14:04 ET $HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB
NXTC) related to its merger with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately
More news about: Monteverde & Associates PC
Jul 21, 2026, 14:51 ET Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders?
multimedia:https://www.prnewswire.com/news-releases/are-crnx-veee-nxtc-tcbk-obtaining-fair-deals-for-their-shareholders-302831187.htmlSOURCE
More news about: Halper Sadeh LLP
Jul 14, 2026, 13:34 ET $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)
NXTC) related to its merger with Avere Therapeutics, Inc. Upon closing of the proposed transaction, NextCure shareholders are expected to own approximately
More news about: Monteverde & Associates PC
Jul 14, 2026, 11:41 ET Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, July 14, 2026 /PRNewswire/ -- Ademi LLP is investigating NextCure (NASDAQ: NXTC) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Avere Therapeutics.
More news about: Ademi LLP